【24h】

Validation of depression screening scales in patients with CKD.

机译:CKD患者抑郁筛查量表的有效性。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Depressive symptoms, assessed by using self-report scales, are present at a striking rate of 45% in patients with chronic kidney disease (CKD) at dialysis therapy initiation. These scales may emphasize somatic symptoms of anorexia, sleep disturbance, and fatigue, which may coexist with chronic disease symptoms and lead to overestimation of depression diagnosis. No study has validated these scales in patients with CKD before dialysis therapy initiation. STUDY DESIGN: We conducted a diagnostic test study in participants with CKD to investigate the screening characteristics of 2 depression self-report scales against a gold-standard structured psychiatric interview. SETTING & PARTICIPANTS: 272 consecutively recruited outpatients with stages 2 to 5 CKD not treated by dialysis were studied. INDEX TESTS: The Beck Depression Inventory (BDI) and the 16-item Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR(16)) depression screening scales were administered to all participants. REFERENCE TEST: A structured Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition)-based interview, the Mini International Neuropsychiatric Interview, was administered by trained persons blinded to self-report scale scores. RESULTS: 57 of 272 (21%) patients had major depression according to the reference test. The best cutoff scores by means of receiver/responder operating characteristic curves to identify a major depressive episode were 11 for the BDI and 10 for the QIDS-SR(16). Sensitivities were 89% (95% confidence interval [CI], 78 to 96; BDI) and 91% (95% CI, 80 to 97; QIDS-SR(16)), whereas specificities were 88% (95% CI, 83 to 92; BDI) and 88% (95% CI, 83 to 92; QIDS-SR(16)). The positive and negative likelihood ratios for these cutoff scores were 7.6 and 0.1 (BDI) and 7.5 and 0.1 (QIDS-SR(16)). LIMITATIONS: Single-center study and a sample not representative of US demographics. CONCLUSIONS: We found that a BDI score of 11 or higher was a sensitive and specific cutoff value for identifying a major depressive episode in patients with CKD not on dialysis therapy. Both the BDI and QIDS-SR(16) are effective screening tools.
机译:背景:使用自我报告量表评估的抑郁症状在开始透析治疗的慢性肾脏病(CKD)患者中的发生率为45%。这些量表可能会强调厌食,睡眠障碍和疲劳等躯体症状,这些症状可能与慢性疾病症状并存,并导致对抑郁症诊断的高估。在透析治疗开始之前,尚无研究对CKD患者的这些量表进行验证。研究设计:我们对患有CKD的参与者进行了诊断测试研究,以针对金标准结构性精神病学访谈调查2个抑郁症自我报告量表的筛查特征。地点和参与者:272例未接受透析治疗的连续2至5期CKD的门诊患者进行了研究。指数测试:对所有参与者进行了贝克抑郁量表(BDI)和抑郁症症状自评量表(QIDS-SR(16))16个项目的快速量表。参考测试:基于结构化的《精神疾病诊断和统计手册》(第四版),《 Mini International Neuropsychiatric Interview》由不了解自我报告量表评分的受过培训的人员进行管理。结果:根据参考测试,在272名患者中有57名(21%)患有重度抑郁症。通过接收器/响应器操作特征曲线确定主要抑郁发作的最佳截止评分是BDI为11,QIDS-SR为10(16)。敏感性为89%(95%置信区间[CI],从78至96; BDI)和91%(95%CI,从80至97; QIDS-SR(16)),而特异性为88%(95%CI,83)至92; BDI)和88%(95%CI,83至92; QIDS-SR(16))。这些截断分数的正似然比和负似然比分别为7.6和0.1(BDI),7.5和0.1(QIDS-SR(16))。局限性:单中心研究和不代表美国人口统计学的样本。结论:我们发现BDI得分11或更高是确定未接受透析治疗的CKD患者主要抑郁发作的敏感且特定的临界值。 BDI和QIDS-SR(16)都是有效的筛选工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号